| Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell–mediated inflammation and immunosuppression W Xu, J Dong, Y Zheng, J Zhou, Y Yuan, HM Ta, HE Miller, M Olson, ... Cancer immunology research 7 (9), 1497-1510, 2019 | 119 | 2019 |
| Signaling by Fyn-ADAP via the Carma1–Bcl-10–MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells K Rajasekaran, P Kumar, KM Schuldt, EJ Peterson, B Vanhaesebroeck, ... Nature immunology 14 (11), 1127-1136, 2013 | 112 | 2013 |
| IQGAP1: Insights into the function of a molecular puppeteer AMA , Kristina M. Schuldt, Kamalakannan Rajasekaran, David Hwang, Matthew J ... Molecular Immunology 65 (2), 336–349, 2015 | 98 | 2015 |
| Clinical relevance of natural killer cells following hematopoietic stem cell transplantation JM Palmer, K Rajasekaran, MS Thakar, S Malarkannan Journal of Cancer 4 (1), 25, 2013 | 92 | 2013 |
| Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes A Awasthi, A Samarakoon, H Chu, R Kamalakannan, LA Quilliam, ... Journal of Experimental Medicine 207 (9), 1923-1938, 2010 | 63 | 2010 |
| IQGAP1: a regulator of intracellular spacetime relativity S Malarkannan, A Awasthi, K Rajasekaran, P Kumar, KM Schuldt, ... The Journal of Immunology 188 (5), 2057-2063, 2012 | 60 | 2012 |
| IL-22: an evolutionary missing-link authenticating the role of the immune system in tissue regeneration P Kumar, K Rajasekaran, JM Palmer, MS Thakar, S Malarkannan Journal of Cancer 4 (1), 57, 2013 | 52 | 2013 |
| Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner S Milanovich, J Peterson, J Allred, C Stelloh, K Rajasekaran, J Fisher, ... Experimental hematology 43 (1), 53-64. e8, 2015 | 49 | 2015 |
| Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells K Rajasekaran, V Xiong, L Fong, J Gorski, S Malarkannan PloS one 5 (9), e12635, 2010 | 48 | 2010 |
| Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy K Rajasekaran, MJ Riese, S Rao, L Wang, MS Thakar, CL Sentman, ... Frontiers in Immunology, Cancer Immunity and Immunotherapy, 2016 | 40 | 2016 |
| Transforming growth factor-β-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production K Rajasekaran, H Chu, P Kumar, Y Xiao, M Tinguely, A Samarakoon, ... Journal of Biological Chemistry 286 (36), 31213-31224, 2011 | 37 | 2011 |
| IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection P Kumar, K Rajasekaran, A Nanbakhsh, J Gorski, MS Thakar, ... Scientific reports 9 (1), 4984, 2019 | 31 | 2019 |
| MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner C Du, J Bevers, R Cook, TN Lombana, K Rajasekaran, M Matsumoto, ... Journal for ImmunoTherapy of Cancer 7, 1-13, 2019 | 21 | 2019 |
| Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. YSS , So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA PLoS One, 2014 | 17 | 2014 |
| Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells K Rajasekaran, X Guan, A Tafazzol, H Hamidi, M Darwish, M Yadav Translational Oncology 27, 101559, 2023 | 1 | 2023 |
| Correction: Corrigendum: Signaling by Fyn-ADAP via the Carma1–Bcl-10–MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells K Rajasekaran, P Kumar, KM Schuldt, EJ Peterson, B Vanhaesebroeck, ... Nature Immunology 15 (2), 205-205, 2014 | 1 | 2014 |
| Novel PI (3) K-p85α/p110δ-ITK-LAT-PLC-γ2 and Fyn-ADAP-Carma1-TAK1 Pathways Define Reverse Signaling via FasL P Kumar, K Rajasekaran, S Malarkannan Critical Reviews™ in Immunology 44 (1), 2024 | | 2024 |
| Integrative Analysis of the Tumor and Microenvironment to Model the Molecular Heterogeneity Underlying the Response to Cevostamab in Relapsed/Refractory Multiple Myeloma H Hamidi, R Nakamura, S Roy, K Rajasekaran, G Diaz, C Dos Santos, ... Blood 142, 3305, 2023 | | 2023 |
| Immune checkpoint protein VISTA controls antitumor immunity via regulating Toll-like receptor signaling and myeloid cells-mediated inflammation. W Xu, Y Zheng, J Zhou, Y Yuan, HM Ta, J Dong, HE Miller, M Olson, ... CANCER IMMUNOLOGY RESEARCH 8 (4), 75-76, 2020 | | 2020 |
| Abstract A82: Immune checkpoint protein VISTA controls antitumor immunity via regulating Toll-like receptor signaling and myeloid cells-mediated inflammation W Xu, Y Zheng, J Zhou, Y Yuan, HM Ta, J Dong, HE Miller, M Olson, ... Cancer Immunology Research 8 (4_Supplement), A82-A82, 2020 | | 2020 |
